BASIC AND CLINICAL STUDIES ON RU 28965

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement4; pp. 674 - 684
• Main Authors: YAMANE, NOBUO, KANEKO, AKIHIRO, MORIHANA, KENJI, TOMITA, FUMISADA, OHTA, YOSHIHIDE, SHIGEHARA, SATOSHI, SASAKI, JIRO, UEMATSU, MASATAKA, SEKIGUCHI, TOKIKO, SHIIKI, KAZUO, YOSHIDA, TOSHIHIRO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement4_674

We conducted basic and clinical studies on RU 28965. 1. Distribution of RU 28965 in plasma, gingiva and mandibular bone was measured in patients given_this agent orally at 150 mg. The peak concentration in plasma was 4.9μg/ml at 240 min, in gingiva 4.9μg/g at 300 min and in mandibular bone 3.5μg/g at 300 min. 2. RU 28965 was given orally to 60 patients with orofacial odontogenic disease in a daily dose of 200 or 300 mg b. i. d. before morning and evening meals for 3-8 days. The results obtained with a daily dose of 300 mg were excellent in 7 cases, good in 39 and poor in 8, the efficacy rate being 85.2%. The antibacterial activity of RU 28965 was determined against 63 strains isolated from 32 cases. RU 28965 showed good antibacterial activity against Gram-positive bacteria except macrolide-resistant strains. 3. Neither side-effects nor abnormal changes in clinical examinations were observed except one case of slightly ele vated S-GOT and S-GPT. In view of these results, we consider RU 28965 a useful antibiotic in the treatment of acute bacterial infections in the odontogenic region.